Bibliografia

(Decreto del Ministero della sanità, 24 maggio 2001)

Bathon JM, Martin RW, Fleishmann RM, Tesser JR, Schiff HM, Keystone EC: A comparison of Etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586-93

Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement injuvenile arthritis. Arthritis Rheum. 1997; 40: 1202-9

Lipsky PE et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis - Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343 (22): 1594-602.

Lovell DJ et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000; 342 (11): 763-9.

Maini et al. Infliximab (chimeric anti-TNF monoclonal antibody) versus placebo in RA patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999; 354: 1932-39.

Moreland et al. Etanercept therapy in rheumatoid arthritis. Ann Intern Med 1999; 130: 478-86.

Pincus T. The understimated long term medical and economic consequences of RA. Drugs 1995; 50 (suppl. 1): 1-74.

Weinblatt et al. Trial of etanercept, a recombinant TNF receptor: Fc fusion protein in patients with rheumatoid arthritis receiving methotrexate. NEJM 1999; 340: 252-259.

Wolfe F et al. The long term outcomes of rheumatoid arthritis. Arthritis Rheum 1998; 41: 1072-82

Wolfe F et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994; 37: 481-9

Altri riferimenti bibliografici di interesse

Arnett FC, Edworty SM, Block DA et al. The ARA 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31: 315-324.

Choy EHS, Panayi GS: Cytochine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344: 907-16

Cimmino MA, Parisi M, Moggiana G, Mela GS, Accardo S: Prevalence of rheumatoid arthritis in Italy: the Chaivari study. Ann Rheum Dis 1998; 57: 315-18

Emery P, Panayi G, Sturrock R, Williams B: Targeted therapies in rheumatoid arthritis: the need for action. Rheumatology 1999; 38: 911-2.

Dougados M et al. Combination therapy in early RA. AN RCT of sulfasalazine and methotrexate compared with the single components. Ann Rheum Dis 1999; 58: 220-5.

Felson DT, Anderson JJ, Boers M et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35

Jonsson B et al. Locomotor status and costs in destructive RA. Acta Orthop scand 1992; 63: 207-12.

Maini et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis monoclonal antibody combined with low dose methotrexate in RA. Arthritis Rheum 1998; 41: 1552-63.

McIntosh E. The cost of reumathoid arthritis. Br J Rheumatol 1996; 35: 781-90.

Montanelli R: L'artrite reumatoide in cifre. Il Sofe 24 ore Sanità, 6-12 febbraio 2001; 25.

Pasero G, Priolo F, Marubini E et al. Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A. Arthritis Rheum 1996; 39: 1006-15

Prevoo MLL, Van't Hoff MA, Kuper HH, Van Leeuwen MA, Van de Putte LBA, Van Riel PLCM. Modified Disease Activity Scores that include twenty-eight joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.

Salaffi F, Peroni M, Ferraccioli GF . Discriminating ability of composite indices for measuring disease activity in rheumatoid arthritis: a comparison of the Chronic Arthritis Systemic Index, Disease Activity Score and Thompson's articular index. Rheumatology 2000; 39: 90-6

Silman A, Klareskog L, Breedeld F, Bresnihan B, Maini R, Van Riel P, Symmons D. Proposal of establish a register for the long term surveillance of advers events in patients with rheumatic disease exposed to biological agents: the EULAR Surveillance Register for Biological Compounds. Ann Rheum Dis 2000; 59: 419-20

Smolen et al. Efficacy and safety of leflunomide compared with placebo and sulfasalazine in active rheumatoid arthritis: a double blind randomized trial. Lancet 1999; 353: 259-66.

Sokka T et al. Work disability in RA 10 years after the diagnosis. J Rheumatology 1999; 25: 1681-5.

Strand V, Cohen S, Schiff M et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999; 159: 2542-2550.

Tugwell et al. Combination therapy with cyclosporin and methrotrexate in severe RA NEJM 1995; 333: 137-41.

Van Gestel AM, Haagsma CJ, Van Riel PLCM. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998, 41; 1845-1850.

Wiles N, Symmons DP, Harrison B, Barrett E. Barrett JH, Scott DG, Silman AJ. Estimating the incidence of rheumatoid arthritis: trying to hit a moving target? Arthritis Rheum. 1999; 42:1339-46.